Emergence of new pandemic gII.4 sydney norovirus strain correlateswith escape from herd immunity

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1877-1887

  Debbink, Kari ^a   Lindesmith, Lisa C ^b   Donaldson, Eric F ^b   Costantini, Veronica ^c   Beltramello, Martina ^d   Corti, Davide ^d,e   Swanstrom, Jesica ^b   Lanzavecchia, Antonio ^d   Vinjé, Jan ^a   Baric, Ralph S ^b,c,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^e 2107 McGavran Greenberg ^*  (Switzerland)

^f NONE   (United States)

Author keywords

GII.4 sydney; Norovirus; Viral evolution; Virus emergence; Virus like particles

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PURIFICATION; ANTIGEN STRUCTURE; ANTIGENIC VARIATION; ANTIGENICITY; ARTICLE; CROSS REACTION; GII 4 SYDNEY NOROVIRUS; HERD IMMUNITY; IMMUNOREACTIVITY; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

GII.4 SYDNEY; NOROVIRUS; VIRAL EVOLUTION; VIRUS EMERGENCE; VIRUS-LIKE PARTICLES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BIOLOGICAL EVOLUTION; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; EPITOPES; GASTROENTERITIS; GENETIC VARIATION; GENOME, VIRAL; HUMANS; HYBRIDOMAS; IMMUNITY, HERD; IMMUNOGLOBULIN G; MICE; NOROVIRUS; PANDEMICS; SPECIES SPECIFICITY;

EID: 84888611899     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit370     Document Type: Article

References (45)

1. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011; 17:7-15.
2. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006; 346:312-23.
3. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011; 60:1-18.
4. Fankhauser RL, Monroe SS, Noel JS, et al. Epidemiologic and molecular trends of Norwalk-like viruses associated with outbreaks of gastroenteritis in the United States. J Infect Dis 2002; 186:1-7.
5. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705.
6. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol 2012; 86:1214-26.
7. Lindesmith LC, Debbink K, Swanstrom J, et al. Monoclonal antibodybased antigenic mapping of norovirus GII.4-2002. J Virol 2012; 86: 873-83.
8. Lindesmith LC, Costantini V, Swanstrom J, et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 2013; 87:2803-13.
9. Vinje J, Altena SA, Koopmans MP. The incidence and genetic variability of small round-structured viruses in outbreaks of gastroenteritis in the Netherlands. J Infect Dis 1997; 176:1374-8.
10. Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J Infect Dis 1999; 179:1334-44.
11. Widdowson MA, Cramer EH, Hadley L, et al. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus-United States, 2002. J Infect Dis 2004; 190:27-36.
12. Bull RA, Tu ET, McIver CJ, Rawlinson WD, White PA. Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis. J Clin Microbiol 2006; 44:327-33.
13. Kroneman A, Vennema H, Harris J, et al. Increase in norovirus activity reported in Europe. Euro Surveill 2006; 11: 1.
14. Phan TG, Kuroiwa T, Kaneshi K, et al. Changing distribution of norovirus genotypes and genetic analysis of recombinant GIIb among infants and children with diarrhea in Japan. J Med Virol 2006; 78:971-8.
15. Siebenga J, Kroneman A, Vennema H, Duizer E, Koopmans M. Foodborne viruses in Europe network report: The norovirus GII.4 2006b (for US named Minerva-like, for Japan Kobe034-like, for UK V6) variant now dominant in early seasonal surveillance. Euro Surveill 2008; 13.
16. Centers for Disease Control and Prevention. Norovirus activity- United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:842-6.
17. Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinje J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis 2011; 17:1389-95.
18. Centers for Disease Control and Prevention. Notes from the field: emergence of new norovirus strain GII.4 Sydney-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:55.
19. van Beek J, Ambert-Balay K, Botteldoorn N, et al. Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012. Euro Surveill 2013; 18.
20. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999; 286:287-90.
21. Lindesmith LC, Donaldson EF, Lobue AD, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31.
22. Chen R, Neill JD, Estes MK, Prasad BV. X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc Natl Acad Sci U S A 2006; 103:8048-53.
23. Cao S, Lou Z, Tan M, et al. Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol 2007; 81:5949-57.
24. Lochridge VP, Jutila KL, Graff JW, Hardy ME. Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J Gen Virol 2005; 86:2799-806.
25. Rougemont A, Ruvoen-Clouet N, Simon B, et al. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol 2011; 85:4057-70.
26. Choi JM, Hutson AM, Estes MK, Prasad BV. Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A 2008; 105:9175-80.
27. Shanker S, Choi JM, Sankaran B, Atmar RL, Estes MK, Prasad BV. Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol 2011; 85:8635-45.
28. Marionneau S, Ruvoen N, Moullac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002; 122:1967-77.
29. Lindesmith LC, Donaldson EF, Baric RS. Norovirus GII.4 strain antigenic variation. J Virol 2011; 85:231-42.
30. Bok K, Abente EJ, Realpe-Quintero M, et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J Virol 2009; 83:11890-901.
31. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog 2010; 6:e1000831.
32. Zakikhany K, Allen DJ, Brown D, Iturriza-Gomara M. Molecular evolution of GII-4 norovirus strains. PLoS One 2012; 7:e41625.
33. Allen DJ, Gray JJ, Gallimore CI, Xerry J, Iturriza-Gomara M. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 2008; 3: e1485.
34. Tian P, Yang D, Jiang X, et al. Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J Appl Microbiol 2010; 109:1753-62.
35. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002; 76:12335-43.
36. Nurminen K, Blazevic V, Huhti L, et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011; 83:525-31.
37. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-8.
38. Siebenga JJ, Vennema H, Renckens B, et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol 2007; 81:9932-41.
39. Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends Microbiol 2011; 19:233-40.
40. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev 2008; 225:190-211.
41. Corti D, Suguitan AL Jr., Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73.
42. Allen DJ, Noad R, Samuel D, Gray JJ, Roy P, Iturriza-Gomara M. Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol J 2009; 6:150.
43. Tan M, Xia M, Cao S, et al. Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology 2008; 379:324-34.
44. Yang Y, Xia M, Tan M, et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol 2010; 84:9595-607.
45. Santos RP, Chao J, Nepo AG, et al. The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia. Pediatrics 2012; 130:e1695-9.